睿智医药(300149) - 2022 Q1 - 季度财报

Revenue and Profitability - Revenue for Q1 2022 was CNY 386.30 million, a decrease of 0.87% compared to CNY 389.71 million in the same period last year[4] - Net profit attributable to shareholders increased by 480.41% to CNY 9.47 million from CNY 1.63 million year-on-year[4] - Net profit excluding non-recurring items rose by 281.04% to CNY 8.19 million, compared to a loss of CNY 4.52 million in the previous year[4] - Basic and diluted earnings per share increased by 475.76% to CNY 0.019 per share from CNY 0.0033 per share year-on-year[4] - The company reported a net profit margin of approximately 4.0% for Q1 2022, compared to 3.8% in the previous year[22] - The net profit for the first quarter of 2022 was CNY 9,416,742.22, a significant increase compared to CNY 1,593,355.43 in the same period last year, representing a growth of approximately 490%[23] - Basic and diluted earnings per share were both CNY 0.019, up from CNY 0.003 in the previous year, marking a growth of 533%[24] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 4.22 billion, a slight decrease of 0.05% from CNY 4.22 billion at the end of the previous year[4] - Total assets decreased slightly to CNY 4,215,614,127.91 from CNY 4,217,591,526.68[19] - Total liabilities were CNY 2,223,042,149.89, a slight decrease from CNY 2,228,514,640.12[20] - Shareholders' equity increased to CNY 1,992,571,978.02 from CNY 1,989,076,886.56[20] Cash Flow - Cash flow from operating activities decreased by 46.26% to CNY 34.94 million from CNY 65.03 million in the same period last year[11] - The cash flow from operating activities was CNY 34,944,776.30, a decline from CNY 65,025,423.75, representing a decrease of about 46%[26] - The cash and cash equivalents at the end of the period were CNY 53,582,669.86, a decrease from CNY 285,075,716.31 at the end of the previous year[26] - The company incurred a total of CNY 115,633,226.13 in cash outflows from financing activities, compared to CNY 147,188,755.67 in the same period last year, indicating a reduction of about 21.5%[26] - The company’s cash flow from financing activities decreased by 250% to -CNY 95.63 million, mainly due to a reduction in bank borrowings[11] Operating Performance - Total operating revenue for Q1 2022 was CNY 386,301,922.70, a decrease of 0.1% compared to CNY 389,706,314.16 in the same period last year[22] - Total operating costs for Q1 2022 were CNY 368,984,885.99, down 6.4% from CNY 394,135,991.16 year-over-year[22] - Operating costs included CNY 233,431,931.86 in cost of goods sold, a decrease of 15.3% from CNY 275,727,777.91 in the previous year[22] - The total revenue from operating activities was CNY 342,149,405.36, down from CNY 415,774,844.21 in the previous year, indicating a decrease of approximately 17.6%[24] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 23.81% to CNY 414.98 million, primarily due to an increase in service fees receivable[8] - Accounts receivable increased to CNY 414,977,425.27 from CNY 335,165,521.71, representing a growth of 23.8%[18] - Inventory at the end of Q1 2022 was CNY 77,517,458.55, an increase of 12.5% from CNY 68,812,426.27 at the beginning of the year[18] Expenses - The company’s management expenses rose by 22.84% to CNY 67.84 million, mainly due to increased initial operating costs of the Jiangsu Innovation Biopharmaceutical platform[10] - Research and development expenses increased to CNY 28,398,046.08 from CNY 24,806,172.55, reflecting a year-over-year increase of about 23%[23] Investment Income - The company’s investment income decreased by 89.80% to CNY 440,243.17, primarily due to reduced investment returns from ShangPharma Capital LP[10] - The investment activities resulted in a net cash outflow of CNY 38,329,695.69, an improvement from a net outflow of CNY 89,865,489.00 in the previous year[26] Other Financial Metrics - The company reported a comprehensive income of CNY 8,558,100.36, compared to a loss of CNY 1,975,964.26 in the same quarter last year[24] - The company experienced a foreign exchange loss of CNY 858,641.86, compared to a loss of CNY 3,569,319.69 in the same quarter last year[24]